Inito, a medical technology startup, announced securing $6 million in a Series A funding round led by Fireside Ventures.
Launched in 2015 and based in Bengaluru, Inito aids women in tracking fertility hormones and delivers personalized analytics on reproductive health through its main product, the Fertility Monitor.
Inito integrates hardware, biotechnology, and machine learning, thereby elevating the accuracy, reliability, and density of test strips. Consequently, this innovative approach enables the simultaneous measurement of multiple parameters on a single testing platform. This holistic enhancement contributes to a more comprehensive and efficient diagnostic process.
The freshly acquired funds will fuel the global expansion of Inito’s hormone test, enhance analytics through artificial intelligence (AI), and support research and development for new tests. The company’s long-term goal involves providing diagnostic tests for various health concerns through a smartphone-based platform.
“The partnership with Fireside Ventures has not only provided crucial financial backing but also valuable mentorship and strategic guidance, enabling Inito to build a leading consumer health tech brand for the world from India,” cofounders Aayush Rai and Varun AV said in a joint statement.
